Actively Recruiting
Evaluating LY4395089 with Mirikizumab Compared to Mirikizumab Alone in Adults with Active Crohns Disease
Led by Eli Lilly and Company · Updated on 2026-11-04
60
Participants Needed
71
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a drug called LY4395089, a farnesoid X receptor FXR agonist, when given together with mirikizumab compared to mirikizumab alone in adults with moderately to severely active Crohns disease. This Phase 2 study is part of the IIBD master protocol and is expected to last about 62 weeks. The goal is to better understand how this combination treatment works for this condition. Participants will be assigned to one of two groups one receiving only mirikizumab and the other receiving both LY4395089 orally and mirikizumab intravenously during the first study period. Responders will then stop LY4395089 and receive mirikizumab subcutaneously in the second study period. Mirikizumab is given first via IV and later by a subcutaneous injection. The study compares these treatment approaches to assess differences in response. During the study, participants will undergo assessments including endoscopic evaluation to measure response up to week 12, clinical remission checks, and fecal calprotectin tests to monitor inflammation levels. Researchers will track safety and efficacy throughout the approximately 62-week study duration. Participants will have regular visits for treatment administration and monitoring, with the main focus on the percentage of participants achieving endoscopic response by week 12.
CONDITIONS
Brief Title
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Research Team
T
There may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here